Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO David D. Chang Sells 46,668 Shares

Allogene Therapeutics, Inc. (NASDAQ:ALLO) CEO David D. Chang sold 46,668 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares of the company’s stock, valued at approximately $10,342,075.24. This represents a 0.88 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Allogene Therapeutics Price Performance

Shares of ALLO stock traded down $0.16 during trading hours on Tuesday, hitting $1.69. The company had a trading volume of 3,349,922 shares, compared to its average volume of 3,049,664. The company’s fifty day moving average is $1.93 and its 200 day moving average is $2.31. Allogene Therapeutics, Inc. has a fifty-two week low of $1.32 and a fifty-two week high of $4.74. The stock has a market capitalization of $354.35 million, a PE ratio of -1.08 and a beta of 1.02.

Allogene Therapeutics (NASDAQ:ALLO) last announced its earnings results on Thursday, March 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. Equities analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current year.

Institutional Investors Weigh In On Allogene Therapeutics

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System increased its holdings in shares of Allogene Therapeutics by 6.0% in the 4th quarter. California State Teachers Retirement System now owns 135,554 shares of the company’s stock valued at $289,000 after acquiring an additional 7,685 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Allogene Therapeutics by 18.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 270,559 shares of the company’s stock worth $576,000 after purchasing an additional 41,753 shares during the last quarter. Two Sigma Advisers LP increased its stake in Allogene Therapeutics by 12.1% in the fourth quarter. Two Sigma Advisers LP now owns 2,702,200 shares of the company’s stock valued at $5,756,000 after purchasing an additional 291,800 shares during the period. Rafferty Asset Management LLC raised its holdings in shares of Allogene Therapeutics by 15.9% in the fourth quarter. Rafferty Asset Management LLC now owns 367,445 shares of the company’s stock valued at $783,000 after buying an additional 50,499 shares during the last quarter. Finally, Raiffeisen Bank International AG acquired a new stake in shares of Allogene Therapeutics during the fourth quarter worth about $903,000. 83.63% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Friday. Citizens Jmp raised shares of Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research note on Friday. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 target price on shares of Allogene Therapeutics in a report on Friday. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.40.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).